Early Peanut Immunotherapy May Yield Long-Term Benefits
A study on peanut oral immunotherapy (OIT) shows promising long-term benefits for participants who began treatment at a young age. Most participants continued to consume peanuts years later, with significant immune changes observed. While some reported allergic reactions, the overall findings suggest a relative safety in ongoing peanut consumption after early-life OIT.
- ▪80% of participants who received OIT reported eating peanuts at follow-up.
- ▪94% of those participants consumed at least 300 mg of peanut protein per serving.
- ▪Participants who received OIT alone had lower peanut-specific IgE levels and higher IgG4 levels compared to those who received placebo.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Most participants who received peanut oral immunotherapy (OIT) at 1-3 years of age continued peanut consumption years later and had persistent immune changes, with only some reporting allergic reactions.METHODOLOGY:Researchers followed up 58 participants who had received peanut OIT and 20 who received placebo in a previous trial to assess the long-term outcomes of therapy initiated at 1-3 years of age.Participants completed surveys on current peanut intake and allergic reactions. Overall, 58 participants provided blood for peanut- and Ara h 2-specific antibody testing (Ara h 2 is a protein found in peanuts), and 49 underwent skin-prick testing.The primary outcome was the consumption of at least 300 mg of peanut protein per serving at follow-up.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
